^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    calotatug ginistinag (XMT-2056)

    i
    Other names: XMT-2056
    Company:
    GSK, Mersana
    Drug class:
    HER2-targeted antibody-drug conjugate, STING agonist
    Related drugs:
    2ms
    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 (clinicaltrials.gov)
    P1, N=162, Recruiting, Mersana Therapeutics | Suspended --> Recruiting | Trial completion date: Nov 2025 --> Apr 2027 | Trial primary completion date: Nov 2025 --> Apr 2027
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression
    |
    calotatug ginistinag (XMT-2056)
    2years
    XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab (AACR 2022)
    To this end, administration of an XMT-2056 surrogate ADC in combination with an anti-PD1 agent improved anti-tumor activity in a ratHER2-engineered EMT-6 syngeneic mouse model. Together these data support the potential of XMT-2056 both as a monotherapy and in combination with other HER2 targeted agents as well as checkpoint inhibitors.
    Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • calotatug ginistinag (XMT-2056)